Clinical trials: Ebola
Ebola Virus
Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)
This is a study of the anti-Ebola vaccine vesicular stomatitis virus (VSV) ZEBOV (Zaire ebolavirus) also known as V920 and BPSC-1001.
- Trial name
- NCT02269423
- Testing
- V920
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and…
- Trial name
- NCT02598388
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in United States, Kenya and 4 more
- Volunteers
- 578 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Virus
Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Ebola virus has infected and killed people, mostly in Africa. In 2014, the Ebola virus has affected several thousand people. There is no approved effective way to treat or prevent Ebola.
- Trial name
- NCT02314923
- Testing
- V920 Vaccine
- Volunteers
- 513 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ebola Virus Disease
Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination
This is a clinical trial in which healthy volunteers will be administered two experimental Ebola vaccines: ChAd3-EBO Z and MVA-EBO Z.
- Trial name
- NCT02485912
- Testing
- ChAd3-EBO Z, MVA-EBO Z
- Where
- Senegal
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola Virus
Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
RV 508 was a Phase I, open-label, dose-escalation study to examine the safety, tolerability and immunogenicity of an investigational Ebola vaccine in healthy adults.
- Trial name
- NCT04041570
- Testing
- cAd3-EBO S vaccine
- Where
- Uganda
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola
A Study of a New Vaccine Against Two Types of Ebola
An open-label, non-randomised, dose escalation, first-in-human, single centre, phase I clinical trial to determine the safety and immunogenicity of a bivalent ChAdOx1 vectored vaccine against Zaire and Sudan Ebola virus species…
- Trial name
- NCT05079750
- Testing
- ChAdOx1 biEBOV
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
The purpose of this study is to assess the safety, tolerability and immunogenicity of three heterologous prime-boost regimens for Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo.
- Trial name
- NCT02564523
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 1,075 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Virus Disease
Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola
This Phase 2 study aims to improve preparedness for future Ebola outbreaks by vaccination of a well-known population at risk, ie, a cohort of health care providers (HCP) (such as primary, emergency, and community health care…
- Trial name
- EBOVAC3DRC (NCT04186000)
- Testing
- Ad26.ZEBOV vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 699 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Ebola
A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 and 3…
- Trial name
- NCT04228783
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in United States
- Volunteers
- 974 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Viruses
Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)
Ebola virus has infected and killed people, mostly in Africa. In 2014, the Zaire ebolavirus (ZEBOV) has affected several thousand people. There is no approved effective way to treat or prevent Ebola.
- Trial name
- NCT02280408
- Testing
- V920
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ebola Viral Disease
A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of 3 vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens.
- Trial name
- NCT02416453
- Testing
- MVA-BN-Filo, Ad26.ZEBOV
- Where
- 11 sites in France, United Kingdom
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Hemorrhagic Fever, Ebola
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
The purpose of the study is to assess the long-term safety profile of Ad26.ZEBOV and MVA-BN-Filo in participants previously exposed to these vaccines in Phase 1, 2, or 3 clinical studies.
- Trial name
- NCT02661464
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 16 sites in United States, Burkina Faso and 5 more
- Volunteers
- 677 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebolavirus Disease
VSV-ZEBOV Geneva Vaccine Trial
The hemorrhagic fever resulting from Ebola infection is frequently fatal; the current Ebola outbreak, still in its ascendant phase, has a mortality rate over 50%. There is no proven therapy or prevention available at this time.
- Trial name
- VSV-ZEBOV (NCT02287480)
- Testing
- VSV-ZEBOV
- Where
- Switzerland
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Prevention of Ebola Infection
Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)
The study evaluated the safety and immunogenicity of 3 consistency lots and a high-dose lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in healthy adults.
- Trial name
- NCT02503202
- Testing
- V920 Consistency Lot A, V920 Consistency Lot B, V920 Consistency Lot C
- Volunteers
- 1,197 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Virus Diseases
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults
The purpose of this study is to assess the safety and immunogenicity of the investigational ChAd3-EBO-Z vaccine administered to approximately 3 000 adults in Africa as a single IM dose Considering the risk of exposure to Ebola…
- Trial name
- NCT02485301
- Testing
- GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
- Where
- 5 sites in Cameroon, Mali and 2 more
- Volunteers
- 3,024 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ebola Virus Disease
Partnership for Research on Ebola VACcinations
The purpose of this study is to evaluate the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) events in children and adults.
- Trial name
- PREVAC (NCT02876328)
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, rVSVΔG-ZEBOV-GP
- Where
- 6 sites in Guinea, Liberia and 2 more
- Volunteers
- 4,789 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
The purpose of this study is to assess the safety and reactogenicity of a heterologous 2-dose regimen utilizing Ad26.ZEBOV (first vaccination; Dose 1) and MVA-BN-Filo (second vaccination; Dose 2) administered intramuscularly (IM)…
- Trial name
- NCT03929757
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, MenACWY
- Where
- 2 sites in Guinea, Sierra Leone
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Virus Diseases
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children
The purpose of this study is to assess the safety and reactogenicity of a single IM dose of the GSK3390107A (ChAd3 EBO-Z) vaccine, overall and in children aged 1 to 5, 6 to 12, and 13 to 17 years, separately.
- Trial name
- NCT02548078
- Testing
- GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A), Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine
- Where
- 2 sites in Mali, Senegal
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Adult Immune Responses to Vaccine
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults
Background: Ebola is a virus that has infected and killed people mostly in West Africa. There is no treatment or prevention for it, but several drugs are being studied.
- Trial name
- NCT03478891
- Testing
- VRC-EBOMAB092-00-AB (MAb114)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)
This is an open-label study evaluating the safety and immunogenicity of a booster dose of Ad26.ZEBOV administered to children who were previously vaccinated with Ad26.ZEBOV followed by MVA-BN-Filo 56 days later.
- Trial name
- NCT04711356
- Testing
- Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection
- Where
- Sierra Leone
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine